Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024

 
• By Andrew McConaghie

Septerna is the best performer of newly launched firms from Q4, with more initial public offerings fuelled by potential interest rate cuts hoped for in 2025.

All signs point to an imminent IPO for Stada (Shutterstock)

More from Financing

More from Start-Ups & SMEs